A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD) or
recommended phase II doses of sapacitabine and seliciclib administered sequentially or
concomitantly. The secondary objectives are to evaluate antitumor activity of this sequential
or concomitant treatment and to explore the pharmacodynamic effect of this treatment in skin
and peripheral blood mononuclear cells.